Cap-Assisted Endoscopic Mucosal Resection for Rectal Neuroendocrine Tumors: An Effective Option

Abstract

<b><i>Introduction:</i></b> The incidence of rectal neuroendocrine tumors (r-NETs) is increasing, and most small r-NETs can be treated endoscopically. The optimal endoscopic approach is still debatable. Conventional endoscopic mucosal resection (EMR) leads to frequent incomplete resection. Endoscopic submucosal dissection (ESD) allows higher complete resection rates but is also associated with higher complication rates. According to some studies, cap-assisted EMR (EMR-C) is an effective and safe alternative for endoscopic resection of r-NETs. <b><i>Aims:</i></b> This study aimed to evaluate the efficacy and safety of EMR-C for r-NETs ≤10 mm without muscularis propria invasion or lymphovascular infiltration. <b><i>Methods:</i></b> Single-center prospective study including consecutive patients with r-NETs ≤10 mm without muscularis propria invasion or lymphovascular invasion confirmed by endoscopic ultrasound (EUS), submitted to EMR-C between January 2017 and September 2021. Demographic, endoscopic, histopathologic, and follow-up data were retrieved from medical records. <b><i>Results:</i></b> A total of 13 patients (male: 54%; <i>n</i> = 7) with a median age of 64 (interquartile range: 54–76) years were included. Most lesions were located at the lower rectum (69.2%, <i>n</i> = 9), and median lesion size was 6 (interquartile range: 4.5–7.5) mm. On EUS evaluation, 69.2% (<i>n</i> = 9) of tumors were limited to muscularis mucosa. EUS accuracy for the depth of invasion was 84.6%. We found a strong correlation between size measurements by histology and EUS (<i>r</i> = 0.83, <i>p</i> < 0.01). Overall, 15.4% (<i>n</i> = 2) were recurrent r-NETs and had been pretreated by conventional EMR. Resection was histologically complete in 92% (n = 12) of cases. Histologic analysis revealed grade 1 tumor in 76.9% (<i>n</i> = 10) of cases. Ki-67 index was inferior to 3% in 84.6% (<i>n</i> = 11) of cases. The median procedure time was 5 (interquartile range: 4–8) min. Only 1 case of intraprocedural bleeding was reported and was successfully controlled endoscopically. Follow-up was available in 92% (<i>n</i> = 12) of cases with a median follow-up of 6 (interquartile range: 12–24) months with no evidence of residual or recurrent lesion on endoscopic or EUS evaluation. <b><i>Conclusion:</i></b>EMR-C is fast, safe, and effective for resection of small r-NETs without high-risk features. EUS accurately assesses risk factors. Prospective comparative trials are needed to define the best endoscopic approach.

Endoscopic Resection of Gastrointestinal Neuroendocrine Tumors: Safe and Effective

“…First, João et al [ 3 ] present a prospective cohort study evaluating the efficacy and safety of cap-assisted EMR (EMR-C) for small (≤10 mm) low-grade rectal NETs (r-NETs). In this single-center cohort study, 13 patients were included during a 4-year period (January 2017 until September 2021), with a 100% complete ER rate and a 92% complete pathological resection (CPR) rate (median lesion size of 6 mm).…”